EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Nada O Othman, Hesham H Abdel-Aal, Wessam A Elsherief, Dina E Farag, Catherine N Hunter, Samy A Alsirafy

Journal of the National Comprehensive Cancer Network · 2025

DOI: 10.6004/jnccn.2025.7033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Nada O Othman und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Palliative Medicine Unit, Department of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Olanzapine, Cachexia, Neoplasms, Anorexia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia.

Methods

This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer and cachexia, scoring ≥4 on the Edmonton Symptom Assessment Scale (ESAS) anorexia item (ESAS-Anorexia) and 5% weight gain (14% vs 0%; P =.008), and the mean [SD] improvement in Functional Assessment of Anorexia/Cachexia Therapy – Anorexia/Cachexia Subscale score was higher (+2.7 [7.4] vs −0.04 [7]; P =.043). The mean [SD] decline in handgrip strength was greater with olanzapine and was significant in per-protocol analysis (−2.8 [4.9] kg vs −0.3 [4.1] kg; P =.027). Anxiety, insomnia, and nausea ( P =.016, P =.034, and P =.039, respectively) were significantly less frequent with olanzapine, whereas grade ≥3 anemia and leukopenia were more frequent ( P =.018 and P =.041, respectively).

Conclusions

A short course of olanzapine 5 mg daily significantly reduces anorexia in patients with incurable cancer and cachexia. Further studies are needed to evaluate its long-term safety and efficacy in cancer cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineCachexiaNeoplasmsAnorexiaHumansFemaleMaleDouble-Blind MethodMiddle AgedQuality of LifeAgedTreatment OutcomeAdult

Substanzen

Olanzapine

Autor:innen und Institutionen

  • 1Palliative Medicine Unit, Department of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
  • 2Departments of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.

Zitieren

APA

Othman, N. O., Abdel-Aal, H. H., Elsherief, W. A., Farag, D. E., Hunter, C. N., & Alsirafy, S. A. (2025). Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7033

Vancouver

Othman NO, Abdel-Aal HH, Elsherief WA, Farag DE, Hunter CN, Alsirafy SA. Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7033

BibTeX
@article{Othman2025,
  author = {Othman, Nada O and Abdel-Aal, Hesham H and Elsherief, Wessam A and Farag, Dina E and Hunter, Catherine N and Alsirafy, Samy A},
  title = {Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  doi = {10.6004/jnccn.2025.7033}
}
Kostenlos starten →